 |
 |
   |
Development Approach
Broad-Acting CompoundsMacuSight strategically focuses its product development efforts on broad-acting small molecules based on the belief that these drugs are best suited to most effectively treat complex ocular diseases and conditions that are associated with multiple underlying factors. Such diseases and conditions include age-related macular degeneration (AMD) and diabetic macula edema (DME), a manifestation of diabetic retinopathy. Whereas highly-specific compounds are limited by targeting only a single disease-causing mechanism, broad-acting drugs have the potential to impact a number of mechanisms simultaneously and inhibit multiple factors in a single process. For example, a highly-specific compound may inhibit only a single process in inflammation or angiogenesis, while a broad-acting compound can inhibit angiogenesis AND proliferation AND inflammation AND fibrosis and also work on multiple processes in these complex pathways. Furthermore, MacuSight is particularly excited about the potential for such broad-acting, small molecules to ultimately address disease prevention when used in combination with minimally-invasive, sustained, local delivery. For this reason, the company intends to develop products designed for disease prevention, as well as treatment. The benefits of MacuSight's focus on broad-acting, small molecules are clearly demonstrated by the company's lead product candidate, a proprietary formulation of sirolimus. |
  "Broad-acting compounds are best suited to treat complex ocular diseases and conditions that often involve multiple underlying factors." |